Please use this identifier to cite or link to this item: http://ri.uaemex.mx/handle20.500.11799/79748
DC FieldValueLanguage
dc.creatorALONDRA ESCUDERO CASTELLANOS-
dc.creatorBLANCA ELI OCAMPO GARCIA-
dc.creatorGUILLERMINA FERRO FLORES-
dc.creatorKEILA ISAAC OLIVE-
dc.creatorCLARA LETICIA SANTOS CUEVAS-
dc.creatorANDREA GUADALUPE OLMOS ORTIZ-
dc.creatorJANICE GARCIA QUIROZ-
dc.creatorROCIO ANGELES GARCIA BECERRA-
dc.creatorLORENZA DIAZ NIETO-
dc.date2017-10-20-
dc.identifierhttp://hdl.handle.net/20.500.11799/79748-
dc.descriptionThis study aimed to synthesize a new 177Lu-iPSMA-RGD heterobivalent radiopharmaceutical, as well as to assess the in vitro radiopharmaceutical potential to target cancer cells overexpressing PSMA and a(v) b(3) integrins. The radiotracer prepared with a radiochemical purity of 98.8 ± 1.0% showed stability in human serum, specific recognition with suitable affinity to PSMA and a(v)b(3) integrins, and capability to inhibit cancer cell proliferation and VEGF signaling (antiangiogenic effect). Results warrant further preclinical studies to establish the 177Lu-iPSMA-RGD potential as a dual therapeutic radiopharmaceutical.-
dc.descriptionCONACyT-CB-2016-01-281526-
dc.languageeng-
dc.publisherJ Radioanal Nucl Chem-
dc.relationDOI 10.1007/s10967-017-5555-9;-
dc.rightsinfo:eu-repo/semantics/openAccess-
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0-
dc.source0236-5731-
dc.subjectPSMA inhibitor-
dc.subjectRGD peptide-
dc.subject177Lu-
dc.subject177Lulabeled PSMA inhibitor-
dc.subject177Lu-labeled RGD-
dc.subjectHeterobivalent radiopharmaceutical-
dc.subjectinfo:eu-repo/classification/cti/3-
dc.titlePreparation and in vitro evaluation of 177Lu-iPSMA-RGD as a new heterobivalent radiopharmaceutical-
dc.typearticle-
dc.audiencestudents-
dc.audienceresearchers-
item.grantfulltextnone-
item.fulltextNo Fulltext-
Appears in Collections:Producción
Show simple item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.